LifeMD Inc
$ 3.73
0.27%
04 Dec - close price
- Market Cap 179,065,000 USD
- Current Price $ 3.73
- High / Low $ 3.84 / 3.64
- Stock P/E N/A
- Book Value 0.03
- EPS -0.25
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.03 %
- ROE -22.43 %
- 52 Week High 15.84
- 52 Week Low 3.42
About
LifeMD, Inc. (LFMD) is a leading telehealth platform based in New York that offers a wide range of direct-to-patient healthcare services, focusing on areas such as men's sexual health, dermatology, and concierge medicine. Through its advanced technology, LifeMD significantly enhances accessibility and personalizes the healthcare experience for patients, capitalizing on the growing demand for convenient telehealth solutions in the U.S. The company is strategically poised to thrive in the expanding telehealth market, with its commitment to improving patient engagement and health outcomes, positioning it as a transformative player in the evolving healthcare landscape.
Analyst Target Price
$9.25
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-05 | 2025-05-06 | 2025-03-10 | 2024-11-07 | 2024-08-07 | 2024-05-08 | 2024-03-11 | 2023-11-08 | 2023-08-09 | 2023-05-12 | 2023-03-22 |
| Reported EPS | -0.0833 | -0.06 | 0.0282 | 0.21 | -0.14 | -0.19 | -0.19 | -0.12 | -0.2 | -0.23 | -0.15 | -0.4 |
| Estimated EPS | -0.0357 | -0.02 | 0.14 | 0.14 | -0.12 | -0.12 | -0.15 | -0.14 | -0.15 | -0.1 | -0.16 | -0.18 |
| Surprise | -0.0476 | -0.04 | -0.1118 | 0.07 | -0.02 | -0.07 | -0.04 | 0.02 | -0.05 | -0.13 | 0.01 | -0.22 |
| Surprise Percentage | -133.3333% | -200% | -79.8571% | 50% | -16.6667% | -58.3333% | -26.6667% | 14.2857% | -33.3333% | -130% | 6.25% | -122.2222% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LFMD
2025-10-18 16:35:05
The Rosen Law Firm is reminding purchasers of LifeMD, Inc. (NASDAQ: LFMD) securities between May 7, 2025, and August 5, 2025, of the October 27, 2025 lead plaintiff deadline for a securities class action. The lawsuit alleges that LifeMD materially overstated its competitive position and was reckless in raising its 2025 guidance due to uncounted rising customer acquisition costs in its RexMD segment and for drugs like Wegovy and Zepbound. Investors who purchased LifeMD securities during this period may be entitled to compensation.
2025-10-18 16:35:00
Rosen Law Firm is encouraging investors of LifeMD, Inc. (NASDAQ: LFMD) who purchased securities between May 7, 2025, and August 5, 2025, to secure legal counsel before the October 27, 2025, lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that LifeMD made materially false and/or misleading statements regarding its competitive position and raised its 2025 guidance without properly accounting for rising customer acquisition costs, leading to investor damages. The firm emphasizes its experience and success in securities class action litigation and invites affected investors to contact them for more information.
2025-10-18 16:35:00
Rosen Law Firm is reminding investors of LifeMD, Inc. (NASDAQ: LFMD) who purchased securities between May 7, 2025, and August 5, 2025, about the October 27, 2025 lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that LifeMD made materially false and/or misleading statements regarding its competitive position and recklessly overstated its 2025 guidance without properly accounting for rising customer acquisition costs. Investors affected by these alleged misstatements are encouraged to secure counsel.
2025-10-18 16:35:00
The Rosen Law Firm reminds investors of LifeMD, Inc. (NASDAQ: LFMD) who purchased securities between May 7, 2025, and August 5, 2025, of the October 27, 2025 lead plaintiff deadline in a securities class action. The lawsuit alleges that LifeMD made materially false and misleading statements regarding its competitive position and its 2025 guidance due to uncounted rising customer acquisition costs in its RexMD segment and for obesity drugs. Investors who suffered damages are encouraged to join the class action to seek compensation.
2025-10-18 15:20:18
Bragar Eagel & Squire, P.C. has announced that a class action lawsuit has been filed against LifeMD, Inc. Investors who purchased LifeMD securities between May 7, 2025, and August 5, 2025, are encouraged to contact the firm to learn about their legal rights and potentially serve as lead plaintiff. The lawsuit alleges that LifeMD made materially false and/or misleading statements regarding its competitive position and 2025 guidance, particularly concerning rising customer acquisition costs in its RexMD segment and for obesity treatment drugs like Wegovy and Zepbound.
2025-10-18 14:00:00
Pomerantz LLP has filed a class action lawsuit against LifeMD, Inc. (NASDAQ: LFMD) on behalf of investors who suffered losses. The lawsuit stems from a significant drop in LifeMD's stock price following an announcement of revised 2025 guidance due to "temporary challenges facing our Rex MD business." Investors who purchased LifeMD securities during the Class Period have until October 27, 2025, to seek appointment as Lead Plaintiff.
